Just 5 years ago, HFpEF was described as the “stepchild” of HF with no approved therapies. Today, there are 5 US FDA therapies:.✅ Empagliflozin (#EMPEROR).✅ Dapagliflozin (#DELIVER).✅ Sotagliflozin (#SOLOISTWHF).✅ Sacubitril/Valsartan (#PARAGONHF).✅ Finerenone (#FINEARTSHF)

Wow, the game has changed! #SURPASSCVOT meets its primary & secondary endpoints in first *head-to-head* CV outcomes trial!. Tirzepatide (dual GLP1/GIP agonist) vs Dulaglutide (GLP-1RA). including 16% lower risk of all cause mortality!.

RT @ankeetbhatt: #CardioKidneyMetabolic (CKM) syndrome is common, affecting >90% of US adults. Can we shape care models to address pt-centr….

RT @drbennisahmed: Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2….

RT @medcentralmd: “Therapies indicated for #HF like finerenone should be continued long term without interruption or premature discontinuat….

RT @JACCJournals: 💊💥 New trial, new strategy: Dapagliflozin + spironolactone packs a bigger biomarker punch in #HFpEF. But what’s the trade….

RT @drbennisahmed: Cardiovascular-Kidney-Metabolic Syndrome: A Paradigm for Value-Based Care. CKM syndrome represents a unifying framework….

RT @SarahChuzi: 🔥🔥 Check out this practical piece on CKM implementation and value-based care!.

RT @EdinaCenko: 📢 Presenting our @LancetRH_Europe Series on CVD Inequalities at #ESCCongress Madrid!.📍 Fri Aug 29 | 13:45–15:00 | Room Zag….

RT @JasonKatzMD: So excited to share this next paper with the readers of @JCFINT - incredible vision and perspective by an amazing authorsh….

RT @noshreza: Our 2nd @JCFINT Article in Press is published! 🚀. This week, @zhermesMD @ankeetbhatt @mvaduganathan walk us through innovativ….

RT @JCFINT: 🚨 New in JCF–I: CKM syndrome affects 90% of US adults and is the #1 driver of cardiovascular morbidity, mortality, and cost. Th….

RT @costplusdrugs: 📢 Generic Entresto is now available at Cost Plus Drugs ❗️. Sacubitril/Valsartan is now on A big….

RT @brendonneuen: Combining SGLT2i & MRAs in Heart Failure and CKD: Playing the Long Game @JACCJournals . Our thoughts in light of recent t….

RT @ankeetbhatt: #HFimpEF is common, but data are limited on #GDMT & outcomes. In @JACCJournals, the largest look at HFimpEF in US to date.….

RT @escardio: In a few weeks, cardiology professionals will gather at #ESCCongress 2025 with #WCCardio for an unforgettable experience. En….

RT @David_Ouyang: We are excited to work with @StanfordDeptMed, @SmidtHeart, @mghliver, and @KPDOR with the support of @American_Heart to r….

RT @carlosguizars: #heartfailure improved EF.⬆️Rising prevalence.🚨Despite partial recovery, risk for MACE remains.🚦Clinical gaps and thera….

RT @NatMetabolism: RESEARCH | @clarissamliu, @DanielJDrucker, M Véniant et al (@Amgen, @SinaiHealth). Part 1: This study and a co-pub delve….

RT @noshreza: Tomorrow is a big day for @JCFINT…. Thank you to the 100+ author groups who have chosen to share their science and perspectiv….

RT @hfcollaboratory: Out now — an analysis led by our #HFC members, the first to evaluate the inclusion of social determinants of health (S….